0001562180-23-000221.txt : 20230105
0001562180-23-000221.hdr.sgml : 20230105
20230105160609
ACCESSION NUMBER: 0001562180-23-000221
CONFORMED SUBMISSION TYPE: 4
PUBLIC DOCUMENT COUNT: 1
CONFORMED PERIOD OF REPORT: 20230103
FILED AS OF DATE: 20230105
DATE AS OF CHANGE: 20230105
REPORTING-OWNER:
OWNER DATA:
COMPANY CONFORMED NAME: Mills Kenneth T.
CENTRAL INDEX KEY: 0001652824
FILING VALUES:
FORM TYPE: 4
SEC ACT: 1934 Act
SEC FILE NUMBER: 001-37553
FILM NUMBER: 23511298
MAIL ADDRESS:
STREET 1: C/O REGENXBIO INC.
STREET 2: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
ISSUER:
COMPANY DATA:
COMPANY CONFORMED NAME: REGENXBIO Inc.
CENTRAL INDEX KEY: 0001590877
STANDARD INDUSTRIAL CLASSIFICATION: BIOLOGICAL PRODUCTS (NO DIAGNOSTIC SUBSTANCES) [2836]
IRS NUMBER: 471851754
FISCAL YEAR END: 1231
BUSINESS ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
BUSINESS PHONE: 240-552-8181
MAIL ADDRESS:
STREET 1: 9804 MEDICAL CENTER DRIVE
CITY: ROCKVILLE
STATE: MD
ZIP: 20850
FORMER COMPANY:
FORMER CONFORMED NAME: REGENXBIO, Inc.
DATE OF NAME CHANGE: 20150116
FORMER COMPANY:
FORMER CONFORMED NAME: ReGenX Biosciences, LLC
DATE OF NAME CHANGE: 20131101
4
1
primarydocument.xml
PRIMARY DOCUMENT
X0306
4
2023-01-03
false
0001590877
REGENXBIO Inc.
RGNX
0001652824
Mills Kenneth T.
C/O REGENXBIO INC.
9804 MEDICAL CENTER DRIVE
ROCKVILLE
MD
20850
true
true
false
false
President and CEO
Common Stock
2023-01-03
4
F
false
9308.00
22.68
D
300536.00
D
Common Stock
2023-01-03
4
A
false
54753.00
0.00
A
355289.00
D
Stock Options (Right to buy)
22.25
2023-01-03
4
A
false
264932.00
0.00
A
2033-01-03
Common Stock
264932.00
264932.00
D
Represents shares of common stock withheld to pay taxes upon the vesting of restricted stock units originally granted to the reporting person on January 4, 2021 and January 3, 2022. The number of shares withheld was determined on January 3, 2023 based on the closing price of the issuer's common stock on December 30, 2022.
Represents shares of common stock underlying a time-based restricted stock unit award (RSU). 25% of the shares subject to this RSU will vest on each of January 1, 2024, January 1, 2025, January 1, 2026 and January 1, 2027 while the recipient provides continuous service to the Issuer.
25% of the shares subject to this option shall vest after 12 months of continuous service with the Issuer. The balance will vest in equal monthly installments over the 48 months following January 3, 2024 while the optionee provides continuous service to the Issuer.
/s/ Patrick J. Christmas as attorney-in-fact
2023-01-05